Waverley Pharma Inc.

DB:5GZ Stock Report

Market Cap: €360.0k

Waverley Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Larry Thiessen

Chief executive officer

CA$45.0k

Total compensation

CEO salary percentage100.0%
CEO tenure4.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Larry Thiessen's remuneration changed compared to Waverley Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$2m

Jun 30 2024n/an/a

-CA$2m

Mar 31 2024n/an/a

-CA$2m

Dec 31 2023CA$45kCA$45k

-CA$2m

Sep 30 2023n/an/a

-CA$1m

Jun 30 2023n/an/a

-CA$910k

Mar 31 2023n/an/a

-CA$693k

Dec 31 2022CA$45kCA$45k

-CA$664k

Sep 30 2022n/an/a

-CA$725k

Jun 30 2022n/an/a

-CA$810k

Mar 31 2022n/an/a

-CA$934k

Dec 31 2021CA$45kCA$45k

-CA$797k

Sep 30 2021n/an/a

-CA$851k

Jun 30 2021n/an/a

-CA$642k

Mar 31 2021n/an/a

-CA$697k

Dec 31 2020CA$33kCA$33k

-CA$706k

Compensation vs Market: Larry's total compensation ($USD31.21K) is below average for companies of similar size in the German market ($USD468.18K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.

CEO

Larry Thiessen

4.8yrs

Tenure

CA$45,000

Compensation

Mr. Larry Thiessen MBA, serves as President and Chief Executive Officer at Waverley Pharma Inc. since February 1, 2020 and also serves as its Director since November 22, 2023. He has extensive pharmaceutic...

Board Members

NamePositionTenureCompensationOwnership
Larry Thiessen
President1.1yrsCA$45.00kno data
Albert Friesen
Chairman of the Board8yrsno data74.61%
€ 268.6k
P. Enns
Independent Director8yrsno data0.19%
€ 666.7
James Kinley
Directorless than a yearno data0.10%
€ 376.7

4.5yrs

Average Tenure

52yo

Average Age

Experienced Board: 5GZ's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 19:35
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Waverley Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution